HomeComparePIRS vs SCHD

PIRS vs SCHD: Dividend Comparison 2026

PIRS yields 14.71% · SCHD yields 3.46%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PIRS wins by $23.5K in total portfolio value
10 years
PIRS
PIRS
● Live price
14.71%
Share price
$13.60
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52.5K
Annual income
$3,650.55
Full PIRS calculator →
SCHD
Schwab U.S. Dividend Equity ETF
● Live price
3.46%
Share price
$30.48
Annual div
$1.06
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$425.95
Full SCHD calculator →

Portfolio growth — PIRS vs SCHD

📍 PIRS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPIRSSCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PIRS + SCHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PIRS pays
SCHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PIRS
Annual income on $10K today (after 15% tax)
$1,250.00/yr
After 10yr DRIP, annual income (after tax)
$3,102.97/yr
SCHD
Annual income on $10K today (after 15% tax)
$294.40/yr
After 10yr DRIP, annual income (after tax)
$362.06/yr
At 15% tax rate, PIRS beats the other by $2,740.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PIRS + SCHD for your $10,000?

PIRS: 50%SCHD: 50%
100% SCHD50/50100% PIRS
Portfolio after 10yr
$40.7K
Annual income
$2,038.24/yr
Blended yield
5.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PIRS right now

PIRS
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-1.7
Piotroski
1/9
SCHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PIRS buys
0
SCHD buys
0
No recent congressional trades found for PIRS or SCHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPIRSSCHD
Forward yield14.71%3.46%
Annual dividend / share$2.00$1.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$52.5K$29.0K
Annual income after 10y$3,650.55$425.95
Total dividends collected$25.1K$3.9K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: PIRS vs SCHD ($10,000, DRIP)

YearPIRS PortfolioPIRS Income/yrSCHD PortfolioSCHD Income/yrGap
1← crossover$12,171$1,470.59$11,226$346.36+$945.00PIRS
2$14,695$1,672.70$12,572$357.38+$2.1KPIRS
3$17,611$1,887.56$14,046$367.84+$3.6KPIRS
4$20,958$2,114.15$15,660$377.73+$5.3KPIRS
5$24,777$2,351.33$17,425$387.07+$7.4KPIRS
6$29,109$2,597.87$19,354$395.86+$9.8KPIRS
7$33,999$2,852.44$21,461$404.13+$12.5KPIRS
8$39,493$3,113.67$23,762$411.89+$15.7KPIRS
9$45,637$3,380.17$26,272$419.15+$19.4KPIRS
10$52,483$3,650.55$29,010$425.95+$23.5KPIRS

PIRS vs SCHD: Complete Analysis 2026

PIRSStock

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Full PIRS Calculator →

SCHDETF

The fund’s goal is to track as closely as possible, before fees and expenses, the total return of the Dow Jones U.S. Dividend 100 Index.

Full SCHD Calculator →
📬

Get this PIRS vs SCHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PIRS vs JEPIPIRS vs OPIRS vs KOPIRS vs MAINPIRS vs VYMPIRS vs DGROPIRS vs VIGPIRS vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.